Research led by Mayo Clinic establishes mortality risk for r
An international research team led by Mayo Clinic has developed a first-of-its-kind model to predict mortality in patients suffering from celiac disease (CD).

The study, headed by Alberto Rubio-Tapia, M.D., Mayo Clinic gastroenterologist, established a five-year survival estimate for patients suffering from refractory celiac disease, a rare and most severe form of the disorder.

“Celiac disease is characterized by intestinal damage induced by the ingestion of gluten in susceptible individuals,” the study states. “Gluten-free diet is an effective therapy for most patients.”

Read More: